荣昌生物：多项成果股价涨 8.50%

和讯网2025-04-24

【荣昌生物早盘股价上涨，多项临床进展受关注】荣昌生物早盘一度涨超 12%，截至发稿，股价上涨 8.50%，报 38.30 港元，成交额 3.34 亿港元。美国临床肿瘤学会 2025 年年会将于 5 月 30 日至 6 月 3 日在美国芝加哥举行，荣昌生物 20 余项肿瘤管线临床进展或阶段性数据入选相关展示，包括维迪西妥单抗联合疗法等临床研究。近日荣昌生物于美国神经病学学会年会现场公布泰它西普用于...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2529649310?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2025-04-24 12:21","share_image_url":"https://static.laohu8.com/9a95c1376e76363c1401fee7d3717173","id":"2529649310","market":"hk","top_or_hot":-1,"title":"荣昌生物：多项成果股价涨 8.50%","media":"和讯网","content":"<div>\n<p>【荣昌生物早盘股价上涨，多项临床进展受关注】荣昌生物早盘一度涨超 12%，截至发稿，股价上涨 8.50%，报 38.30 港元，成交额 3.34 亿港元。美国临床肿瘤学会 2025 年年会将于 5 月 30 日至 6 月 3 日在美国芝加哥举行，荣昌生物 20 余项肿瘤管线临床进展或阶段性数据入选相关展示，包括维迪西妥单抗联合疗法等临床研究。近日荣昌生物于美国神经病学学会年会现场公布泰它西普用于...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025042413265494e086c2&s=b\">网页链接</a>\n\n</div>\n","source":"tencent","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>荣昌生物：多项成果股价涨 8.50%</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n荣昌生物：多项成果股价涨 8.50%\n</h2>\n\n<h4 class=\"meta\">\n\n\n2025-04-24 12:21 北京时间&nbsp;&nbsp;&nbsp;<a href=http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025042413265494e086c2&s=b><strong>和讯网</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>【荣昌生物早盘股价上涨，多项临床进展受关注】荣昌生物早盘一度涨超 12%，截至发稿，股价上涨 8.50%，报 38.30 港元，成交额 3.34 亿港元。美国临床肿瘤学会 2025 年年会将于 5 月 30 日至 6 月 3 日在美国芝加哥举行，荣昌生物 20 余项肿瘤管线临床进展或阶段性数据入选相关展示，包括维迪西妥单抗联合疗法等临床研究。近日荣昌生物于美国神经病学学会年会现场公布泰它西普用于...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025042413265494e086c2&s=b\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK1583","symbol_name":"高瓴概念","start_time":0,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025042413265494e086c2&s=b","article_id":"2529649310","we_media_id":null,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025042413265494e086c2&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2529649310","pubTimestamp":1745468505,"columns":[],"sourceInfo":{"source_id":"tencent","name":"腾讯"},"weMediaInfo":null,"summary":"【荣昌生物早盘股价上涨，多项临床进展受关注】荣昌生物早盘一度涨超 12%，截至发稿，股价上涨 8.50%，报 38.30 港元，成交额 3.34 亿港元。美国临床肿瘤学会 2025 年年会将于 5 月 30 日至 6 月 3 日在美国芝加哥举行，荣昌生物 20 余项肿瘤管线临床进展或阶段性数据入选相关展示，包括维迪西妥单抗联合疗法等临床研究。近日荣昌生物于美国神经病学学会年会现场公布泰它西普用于治疗全身型重症肌无力中国 3 期试验结果，98.1%患者重症肌无力日常活动评分改善≥3 分，交银国际认为，泰它西普 gMGIII 期数据优于已上市竞品，且商业化推广策略清晰。","collect":0,"end_time":0,"defaultTopTitle":"qq.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"688331":"荣昌生物","BK1583":"高瓴概念","09995":"荣昌生物","LU1969619763.USD":"EASTSPRING INV CHINA A SHARES GROWTH \"A\" (USD) ACC","BK1161":"生物科技","BK1574":"生物医药B类股","LU2328871848.SGD":"Eastspring Investments - China A Shares Growth AS SGD"},"translate_title":"Rongchang Bio: Stock price rose 8.50% for multiple achievements","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"688331":0.9,"09995":1},"content_text":"【荣昌生物早盘股价上涨，多项临床进展受关注】荣昌生物早盘一度涨超 12%，截至发稿，股价上涨 8.50%，报 38.30 港元，成交额 3.34 亿港元。美国临床肿瘤学会 2025 年年会将于 5 月 30 日至 6 月 3 日在美国芝加哥举行，荣昌生物 20 余项肿瘤管线临床进展或阶段性数据入选相关展示，包括维迪西妥单抗联合疗法等临床研究。近日荣昌生物于美国神经病学学会年会现场公布泰它西普用于治疗全身型重症肌无力中国 3 期试验结果，98.1%患者重症肌无力日常活动评分改善≥3 分，交银国际认为，泰它西普 gMGIII 期数据优于已上市竞品，且商业化推广策略清晰。","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2529649310","isCrawlerRequest":true}